ストックスクリーナーアプリを入手
14.38
0.92%
-0.14
アフターアワーズ：
14.40
0.02
+0.14%
前日終値:
$14.52
開ける：
$14.55
24時間の取引高:
280.07K
Relative Volume:
0.28
時価総額：
$877.56M
収益：
$10.00M
当期純損益:
$-113.63M
株価収益率:
-7.8434
EPS:
-1.8334
ネットキャッシュフロー:
$-83.28M
1週間 パフォーマンス:
+4.18%
1か月 パフォーマンス:
-4.15%
6か月 パフォーマンス:
-58.53%
1年 パフォーマンス:
-42.96%
1日の値動き範囲:
$14.33
$14.67
1週間の範囲:
$13.98
$14.87
52週間の値動き範囲:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
名前
Janux Therapeutics Inc
セクター
電話
(858) 751-4493
住所
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.39 | 885.49M | 10.00M | -113.63M | -83.28M | -1.8334 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-20 | ダウングレード | Barclays | Overweight → Underweight |
| 2026-04-15 | ダウングレード | UBS | Buy → Neutral |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-10 | 開始されました | Stifel | Buy |
| 2025-09-10 | 開始されました | Truist | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-07-11 | 開始されました | Raymond James | Outperform |
| 2024-12-03 | 繰り返されました | BTIG Research | Buy |
| 2024-12-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-22 | 開始されました | Leerink Partners | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-05-30 | 開始されました | Scotiabank | Sector Perform |
| 2024-03-21 | 開始されました | BTIG Research | Buy |
| 2024-03-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 開始されました | Wedbush | Outperform |
| 2022-11-14 | 開始されました | William Blair | Outperform |
すべてを表示
Janux Therapeutics Inc (JANX) 最新ニュース
Here's Why You Should Add JANX Stock to Your Portfolio Now - Yahoo Finance
JANX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
How (JANX) Movements Inform Risk Allocation Models - Stock Traders Daily
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value - TipRanks
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12 - MSN
Janus Henderson (JANX) discloses 4.2M shares, 6.9% passive stake - Stock Titan
Trading Systems Reacting to (JANX) Volatility - Stock Traders Daily
Insider Sell: Maria Dobek Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus
Janux Therapeutics VP Maria Dobek sells $28,878 in stock By Investing.com - Investing.com Australia
Janux Therapeutics VP Maria Dobek sells $28,878 in stock - Investing.com India
Janux Therapeutics (JANX) VP sells 2,038 shares at $14.17 - Stock Titan
Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts - simplywall.st
How much upside is left in Janux Therapeutics (JANX)? Wall Street analysts think 180.44% - MSN
Janux Therapeutics halts early stage cancer program in 'prudent' move - MSN
State Street (JANX) reports 2.46M shares, a 4.1% stake in Janux Therapeutics - Stock Titan
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target - TipRanks
Lifesci Capital Comments on JANX Q2 Earnings - MarketBeat
LifeSci Capital Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics (JANX) Eps Diluted (TTM) - Zacks Investment Research
Janux Therapeutics (JANX) Losses Reach US$113.6 Million TTM Reinforcing Bearish Narratives - Sahm
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $58 - Moomoo
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $40.41, Implies 178% Upside - TradingView
RBC Raises Janux Therapeutics Price Target to $30 From $27, Keeps Outperform Rating - marketscreener.com
Wedbush Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
Piper Sandler Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Guggenheim Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $58 - Moomoo
Wedbush Adjusts Janux Therapeutics Price Target to $36 From $45, Maintains Outperform Rating - Moomoo
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $40.94, Implies 182% Upside - TradingView
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14 - TipRanks
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights - BioSpace
Janux Therapeutics, Inc. (JANX) reports Q1 loss, lags revenue estimates - MSN
Janux Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BMS partnership boosts cash for Janux Therapeutics (NASDAQ: JANX) despite loss - Stock Titan
Janux Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Milestone payment and strong cash fuel Janux (NASDAQ: JANX) pipeline - Stock Titan
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q1 Revenue $3.7M, vs. FactSet Est of $4.4M - marketscreener.com
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - Yahoo Finance
FMR LLC files 13G/A on JANX (NASDAQ: JANX) for 2.54M shares - Stock Titan
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value - Seeking Alpha
EX-99.1 - SEC.gov
Janux Therapeutics Inc (JANX) 財務データ
収益
当期純利益
現金流量
EPS
1.49%
0.12%
大文字化:
|
ボリューム (24 時間):